Chinook Therapeutics, Inc.

DB:290A Stock Report

Market Cap: €2.6b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Chinook Therapeutics Future Growth

Future criteria checks 2/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Chinook Therapeutics.

Key information

22.6%

Earnings growth rate

28.0%

EPS growth rate

Biotechs earnings growth36.4%
Revenue growth rate63.8%
Future return on equityn/a
Analyst coverage

Good

Last updated10 Aug 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:290A - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202580-247-286-2538
12/31/202413-284-289-26211
12/31/20233-253-290-2435
6/30/20236-246-177-174N/A
3/31/20235-216-146-143N/A
12/31/20226-188-119-117N/A
9/30/202257-118-105-103N/A
6/30/202254-92-104-103N/A
3/31/202254-97-101-99N/A
12/31/202152-103-105-103N/A
9/30/20211-160-124-122N/A
6/30/20211-149-105-104N/A
3/31/20211-114-82-80N/A
12/31/20201-82-57-56N/A
9/30/2020N/A-52-19-19N/A
6/30/2020N/A-54-17-16N/A
3/31/2020N/A-48-16-15N/A
12/31/2019N/A-47-14-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 290A is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 290A is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 290A is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 290A's revenue (63.8% per year) is forecast to grow faster than the German market (3.9% per year).

High Growth Revenue: 290A's revenue (63.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 290A's Return on Equity is forecast to be high in 3 years time


Discover growth companies